These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322 [TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance spectroscopic correlates of progression free and overall survival in "glioblastoma, IDH-wildtype, WHO grade-4". Sacli-Bilmez B; Danyeli AE; Yakicier MC; Aras FK; Pamir MN; Özduman K; Dinçer A; Ozturk-Isik E Front Neurosci; 2023; 17():1149292. PubMed ID: 37457011 [TBL] [Abstract][Full Text] [Related]
5. Identification of IDH and TERTp mutation status using Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773 [TBL] [Abstract][Full Text] [Related]
6. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
7. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas. Lasocki A; Buckland ME; Drummond KJ; Wei H; Xie J; Christie M; Neal A; Gaillard F Neuroradiology; 2022 Dec; 64(12):2295-2305. PubMed ID: 35606654 [TBL] [Abstract][Full Text] [Related]
8. Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors. Majós C; Pons-Escoda A; Naval P; Güell A; Lucas A; Vidal N; Cos M; Bruna J Eur Radiol; 2024 Apr; 34(4):2174-2182. PubMed ID: 37740778 [TBL] [Abstract][Full Text] [Related]
9. Effect of Extent of Resection on Survival of Patients with Glioblastoma, IDH-Wild-Type, WHO Grade 4 (WHO 2021): Systematic Review and Meta-Analysis. Jusue-Torres I; Lee J; Germanwala AV; Burns TC; Parney IF World Neurosurg; 2023 Mar; 171():e524-e532. PubMed ID: 36529434 [TBL] [Abstract][Full Text] [Related]
10. Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma. Minami N; Hong D; Stevers N; Barger CJ; Radoul M; Hong C; Chen L; Kim Y; Batsios G; Gillespie AM; Pieper RO; Costello JF; Viswanath P; Ronen SM Neuro Oncol; 2022 Nov; 24(11):1898-1910. PubMed ID: 35460557 [TBL] [Abstract][Full Text] [Related]
11. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Louis DN; Perry A; Wesseling P; Brat DJ; Cree IA; Figarella-Branger D; Hawkins C; Ng HK; Pfister SM; Reifenberger G; Soffietti R; von Deimling A; Ellison DW Neuro Oncol; 2021 Aug; 23(8):1231-1251. PubMed ID: 34185076 [TBL] [Abstract][Full Text] [Related]
15. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770 [TBL] [Abstract][Full Text] [Related]